Use the hyperlinks, where available to access additional clinical trial information.
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Comparing the Efficacy and Safety of Polatuzumab Vedotin in Combination With Rituximab and CHP (R-CHP) Versus Rituximab and CHOP (R-CHOP) in Previously Untreated Patients With Diffuse Large B-Cell Lymphoma
Participants will be randomised into one of two treatment arms. In the experimental arm, participants will receive R-CHP plus Vincristine placebo and Polatuzumab Vedotin. In the comparator arm, participants will receive R-CHOP plus Polatuzumab Vedotin placebo. All drugs will be administered as per the schedule specified in the respective arm.